Grifols, S.A. (GRF.MC)
Chart Events
Performance Outlook
| Previous Close | 18.41 |
| Open | 18.51 |
| Bid | 17.81 x 0 |
| Ask | 17.80 x 0 |
| Day's Range | 17.78 - 18.70 |
| 52 Week Range | 17.08 - 26.07 |
| Volume | 927,037 |
| Avg. Volume | 923,197 |
| Market Cap | 10.491B |
| Beta (5Y Monthly) | 0.10 |
| PE Ratio (TTM) | 21.74 |
| EPS (TTM) | 0.82 |
| Earnings Date | Jul 30, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | 0.36 (1.61%) |
| Ex-Dividend Date | Jun 03, 2021 |
| 1y Target Est | 25.56 |
- American City Business Journals
Sanford leads boom in jobs, housing along U.S. 1 corridor as cost of living in Raleigh, Durham soars
Over the last few years, Sanford has seen hundreds of new jobs in the life sciences space. The same trend is true for other areas that sit along the U.S. Highway 1 corridor. And it’s that corridor that has added thousands of people over the last decade, with waves of others expected to come.
- PR Newswire
Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals
Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest albumin portfolio innovation, ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations.
- PR Newswire
Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines
Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record of contributing to the health and well-being of people around the world, and the National Service Projects Organization (NSPO) in Egypt today inaugurated the first integrated plasma-supply platform in Africa, the start of a robust plasma infrastructure that will bring self-sufficiency to Egypt while facilitating access to plasma products for the bro
